Antibe Therapeutics, Inc. (ATE.V) (ATBPF) Starts Presentation at LD Micro Main Event
Antibe Therapeutics, Inc. (ATE.V) (OTC: ATBPF) develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. For more information, visit the company's website at www.antibethera.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that…







